Spyre Therapeutics, Inc. Common Stock
Market Cap
8.9B
Short interest (Jul 15)
14.4%
Net Short (Jul 27 ): 0.1%
Borrow Fee
0.26%
↑ 2.8%
Available Shares
1M
↑ 19.0%
Price Chart
Company Overview
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.